Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes

Journal article

Ebola drug discovery continues to be challenging as yet. Proteins of the virus should be targeted at the relevant biologically active site for drug or inhibitor binding to be effective. In this regard, by considering the important role of Ebola virus proteins in the viral mechanisms of this viral disease, the Ebola proteins are selected as our drug targets in this study. The discovery of novel therapeutic molecules or peptides will be highly expensive; therefore, we attempted to identify possible antigens of EBOV proteins by conducting docking-based screening of cell penetrating peptides (CPPs) that have antiviral potential features utilizing Hex software version 8.0.0. The E-value scores obtained in this research were very much higher than the previously reported docking studies. CPPs that possess suitable interaction with the targets would be specified as promising candidates for further in vitro and in vivo examination aimed at developing new drugs for Ebola infection treatment

Authors: Wawina-Bokalanga, T; Vanmechelen, B; Lhermitte, V; Martí-Carreras, J; Vergote, V

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Centers for Disease Control and Prevention
• Journal: Emerging Infectious Diseases
• Volume: 27
• Issue: 1
• Pages: 76-84
• Publication date: 2020-12-03
• DOI: 10.3201/eid2701.202177
• EISSN: 1080-6059
• ISSN: 1080-6040
• Language: English
• Keywords: Immunology; Internal medicine; Biology; Human leukocyte antigen; Virus; Genetics; Gene; Virology; Disease; Allele; Antigen; Antibody; Ebola virus; Medicine